- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Volume 2013 (2013), Article ID 896412, 2 pages
PPARs and Liver Disease
1Division of Gastroenterology, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aoba, Sendai, Miyagi 980-8574, Japan
2Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, 1-1 Seiryo, Aoba, Sendai, Miyagi 980-8574, Japan
3Department of Molecular Microbiology and Immunology, Keck School of Medicine, University Southern California, Los Angeles, CA 90033, USA
4Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
Received 14 January 2013; Accepted 14 January 2013
Copyright © 2013 Yasuteru Kondo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This special issue of PPAR Research contains four interesting reviews and a research article examining the relevance of PPARs to liver diseases. Peroxisome proliferation-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily and have been implicated in a variety of pathologic processes. PPARs require heterodimerization with retinoid X receptors (RXRs) to function. PPARs α/β/δ/γ, with RXR, are important nuclear receptors expressed in the liver and contribute to the control of glucose and lipid metabolism, cell proliferation and inflammation, and so forth. PPARs were considered target molecules of human metabolic disease such as nonalcoholic fatty liver diseases (NAFLDs) including nonalcoholic steatohepatitis (NASH), a condition that might progress to cirrhosis. In this special issue, two review articles mention the relationship between PPARs and NAFLD. In regard to inflammation, a review article summarizes the antioxidant stress and anti-inflammation of PPARα. On the other hand, a research article mentions that PPARγ exacerbated concanavalin A (Con A)-induced liver injury. In our review article, we summarize the relevance of PPARs and hepatocellular carcinoma (HCC) including cancer stem cells. These five articles have interesting and valuable points of views regarding PPARs and liver diseases.
In the review article “Antioxidant stress and anti-inflammation of PPARα on warm hepatic ischemic-reperfusion injury” by Z. Gao and Y. H. Li, the authors focus on hepatic ischemic-reperfusion injury, since PPARα could have a role in organ protection in addition to regulating lipid and lipoprotein metabolism. They concluded that oxidant stress and inflammation are the most critical mechanisms in organ pathophysiology after warm hepatic ischemia reperfusion. The most significant mechanisms of PPARα hepatoprotective abilities have been demonstrated through antioxidant stress and anti-inflammation functions. Moreover, they mention that PPARα agonists such as N-3 polyunsaturated fatty acids, eicosapentaenoic acid, and docosahexaenoic acid could decrease the expression of proinflammatory genes by preventing IκB phosphorylation and NF-κB translocation into the nucleus. On the other hand, Y. Ogawa et al. published the research article “Peroxisome proliferation-activated receptor gamma exacerbates concanavalin A-induced liver injury via suppressing the translocation of NF-κB into the nucleus.” Using a mice model, this article surprisingly shows that the administration of PPARγ ligands exacerbated Con A-induced liver injury. They concluded that PPARγ suppressed the translocation of NF-κB into the nucleus, thereby inhibiting the suppression of liver cell apoptosis. In clinical settings, liver damage would occur with inflammation and apoptosis. Therefore, we need to consider the opposite effects of PPARs on liver injury.
NAFLD, a major cause of progressive liver disease, is increasing worldwide at an alarming rate. Defined by an increased hepatic lipid content, NAFLD varies widely from simple steatosis to NASH and has a strong genetic component. PPARs, including PPARα, PPARγ, and PPARδ, play an important role in hepatic lipid metabolism and also have several genetic variants (polymorphisms). In the review article “Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic fatty liver disease: any role in disease susceptibility?” by P. Dongiovanni et al., the authors conducted a meta-analysis of previously reported evidence based upon which they describe the possible association between PPARs genetic polymorphisms and the susceptibility to NAFLD and NASH in specific subgroups. This review may contribute to new insight into the management of a therapeutic strategy for NAFLD, targeting PPARs. In the review article “Misregulation of PPAR functioning and Its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity” by L. A. Videla and P. Pettinelli, the authors mention that NASH is involved in the misregulation of PPARs signaling, accompanied by PPAR-γ and SREBP-1c-mediated metabolic disturbances (obesity-induced oxidative stress and related long-chain polyunsaturated fatty acid n-3 (LCPUFA n-3) depletion, insulin resistance, hypoadiponectinemia, and ER stress, due to lipogenesis and fatty acid oxidation. Targeting PPAR-α is problematic since fibrates have poor effectiveness, thiazolidinediones have weight gain limitations, and dual PPAR-α/γ agonists have safety concerns. The authors describe that supplementation of LCPUFA n-3 is a novel therapeutic modality since it reduces liver steatosis scores and inflammatory response, since the LCPUFA n-3 depletion reduces PPAR-α, leading to enhanced DNA binding of proinflammatory factors (NF-κB and AP-1) and the progression of steatosis to steatohepatitis.
In our review article “PPAR could contribute to the pathogenesis of hepatocellular carcinoma,” we summarize the relevance of PPARs to the pathogenesis of HCC and cancer stem cells and possible therapeutic options through modifying PPAR signaling, since PPARs could contribute to the mechanisms of cell cycling, anti-inflammatory responses, and apoptosis. Abnormal stimulation of PPARα generates HCC through fatty liver. In HCCs, it is not clear whether PPARγ promotes cancer or can control it. PPARs might be useful target cancer stem cells in inducing the differentiation of HCC, because the expression of PPARs has been implicated in the regulation of the cell cycling of hepatocytes.
In conclusion, we hope that you will find these recent advances in elucidating the roles of PPARs in the various kinds of liver diseases. We expect that the reviews presented in this special issue, on the interplay between PPARs and liver disease, will be highly useful for those with interest in this field.